Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation

NCT02771054 is registered in ClinicalTrials.gov with Göteborg University as lead sponsor.

NCT NCT02771054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02771054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation
Lead sponsor
Göteborg University
Phase
Phase 4
Overall status
Completed
Start date
May 2, 2016
Completion date
July 15, 2018
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv